WuXi Biologics To Invest $60 Million in Biologics Mfg Facility in Singapore
By

WuXi Biologics, part of WuXi AppTec, a Shanghai, China-headquartered contract service provider, plans to invest 80 million Singapore dollars (US $60 million) to establish a biologics manufacturing facility in Singapore. It will be WuXi Biologics’ tenth global drug-substance manufacturing facility.

This facility is being designed to use single-use bioreactors as well as continuous bioprocessing. A total of approximately 4,500-liters of bioreactor capacity will be installed consisting of two bioreactors, each with 2,000 liters of fed-batch capacity, and one bioreactor with 500 liters of perfusion-based continuous bioprocessing capacity. This facility is being designed to handle both clinical and small-volume commercial production. An early-stage bioprocess development laboratory will also be included.

The new manufacturing facility is the company’s first overseas site in Asia and second site outside of China. WuXi plans to hire approximately 150 employees at the facility.

This is the latest in a series of investments by Wuxi Biologics. In May 2018, WuXi Biologics announced plans to build an integrated biologics development, clinical, and commercial manufacturing center in Shijiazhuang, Hebei Province, North China. The initial phase of the center is expected to be operational in 2020. Additionally, in April 2018, WuXi Biologics announced plans to invest EUR 325 million ($392 million) in a new biologics drug-substance manufacturing facility in Mullagharlin, Dundalk, County Louth, Ireland.

Source: WuXi Biologics

Leave a Reply

Your email address will not be published. Required fields are marked *